Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HUGO TORO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1861495541
CMS profile
311436
Location
KATY, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$21.69

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $21.69 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Abbott Laboratories $21.69 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HUGO TORO

NPI 1861495541 · CMS profile ID 311436

Allopathic & Osteopathic Physicians / Internal Medicine

KATY, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1861495541?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HUGO TORO, NPI 1861495541, CMS profile ID 311436. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861495541?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). HUGO TORO, NPI 1861495541, CMS profile ID 311436. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861495541?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
HUGO TORO, NPI 1861495541, CMS profile ID 311436, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1861495541?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $21.69 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Abbott Laboratories $21.6905/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240932473 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $22.65 1
PY2022 $203.34 16
PY2023 $175.18 4
PY2025 $21.69 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2022 Principal investigator $4,399.40 1
PY2020 Principal investigator $75,111.44 43
PY2019 Principal investigator $240,944.88 140

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

140 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novo Nordisk AS $23.06 12/27/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706691959
Principal investigator 1 Novo Nordisk AS $56.66 12/24/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692391
Principal investigator 1 SANOFI US SERVICES INC. $1,270.00 12/23/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691607055
Principal investigator 1 Novo Nordisk AS $17,649.36 12/19/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 692458779
Principal investigator 1 Novo Nordisk AS $23.06 12/19/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706691961
Principal investigator 1 SANOFI US SERVICES INC. $250.00 12/16/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who No dispute reported 06/30/2026 691607043
Principal investigator 1 Novo Nordisk AS $23.06 12/13/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692383
Principal investigator 1 SANOFI US SERVICES INC. $650.00 12/12/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who No dispute reported 06/30/2026 691607022
Principal investigator 1 Novo Nordisk AS $23.06 12/06/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706691967
Principal investigator 1 Novo Nordisk AS $9.99 12/06/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706691969
Principal investigator 1 Novo Nordisk AS $12,507.48 12/05/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 692458777
Principal investigator 1 Novo Nordisk AS $23.06 12/02/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706691963
Principal investigator 1 Novo Nordisk AS $9.99 12/02/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706691965
Principal investigator 1 SANOFI US SERVICES INC. $300.00 11/29/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691609547
Principal investigator 1 Novo Nordisk AS $22.50 11/27/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692341
Principal investigator 1 Novo Nordisk AS $22.50 11/22/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692377
Principal investigator 1 Novo Nordisk AS $3.00 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692243
Principal investigator 1 Novo Nordisk AS $3.00 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692245
Principal investigator 1 Novo Nordisk AS $3.00 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692247
Principal investigator 1 Novo Nordisk AS $3.00 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692249
Principal investigator 1 Novo Nordisk AS $3.00 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692251
Principal investigator 1 Novo Nordisk AS $3.00 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692253
Principal investigator 1 Novo Nordisk AS $3.00 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692255
Principal investigator 1 Novo Nordisk AS $3.00 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692257
Principal investigator 1 Novo Nordisk AS $3.00 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692259
Principal investigator 1 Novo Nordisk AS $5.30 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692261
Principal investigator 1 Novo Nordisk AS $60.00 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692263
Principal investigator 1 Novo Nordisk AS $9.80 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692265
Principal investigator 1 Novo Nordisk AS $9.00 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692267
Principal investigator 1 Novo Nordisk AS $6.50 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692269
Principal investigator 1 Novo Nordisk AS $144.00 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692271
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692277
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692279
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692281
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692283
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692285
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692287
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692289
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692291
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692293
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692295
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692297
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692299
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692301
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692303
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692305
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692307
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692309
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692311
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692313
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692315
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692317
Principal investigator 1 Novo Nordisk AS $3.00 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692319
Principal investigator 1 Novo Nordisk AS $3.00 11/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692321
Principal investigator 1 SANOFI US SERVICES INC. $4,084.00 11/18/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 691609147
Principal investigator 1 SANOFI US SERVICES INC. $5,000.00 11/18/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 691609153
Principal investigator 1 Kowa Research Institute, Inc. $1,000.00 11/07/2019 Non-covered Recipient Entity
Juno Research, LLC
K-877-303 No dispute reported 06/30/2026 629131107
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $3,700.00 11/04/2019 Non-covered Recipient Entity
JUNO RESEARCH LLC
EFC15294 No dispute reported 06/30/2026 690603537
Principal investigator 1 SANOFI US SERVICES INC. $9,400.00 11/04/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691608255
Principal investigator 1 Novo Nordisk AS $9.99 10/31/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692219
Principal investigator 1 Novo Nordisk AS $23.06 10/31/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692221
Principal investigator 1 Novo Nordisk AS $5,150.52 10/29/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 692458767
Principal investigator 1 Kowa Research Institute, Inc. $2,074.30 10/24/2019 Non-covered Recipient Entity
Juno Research, LLC
K-877-301 No dispute reported 06/30/2026 629123627
Principal investigator 1 Novo Nordisk AS $9.99 10/24/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692215
Principal investigator 1 Novo Nordisk AS $23.06 10/24/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692217
Principal investigator 1 Novo Nordisk AS $9.99 10/17/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692211
Principal investigator 1 Novo Nordisk AS $23.06 10/17/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692213
Principal investigator 1 Novo Nordisk AS $23.06 10/16/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692209
Principal investigator 1 Novo Nordisk AS $23.06 10/15/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692207
Principal investigator 1 Novo Nordisk AS $9.99 10/02/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692203
Principal investigator 1 Novo Nordisk AS $23.06 10/02/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692205
Principal investigator 1 Novo Nordisk AS $13.25 10/01/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692195
Principal investigator 1 Novo Nordisk AS $24.95 10/01/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692197
Principal investigator 1 Novo Nordisk AS $7.20 10/01/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692199
Principal investigator 1 Novo Nordisk AS $7.20 10/01/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692201
Principal investigator 1 SANOFI US SERVICES INC. $2,022.00 09/30/2019 Non-covered Recipient Entity
Juno Research LLC
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691572313
Principal investigator 1 Novo Nordisk AS $9.99 09/27/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692187
Principal investigator 1 Novo Nordisk AS $23.06 09/27/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692189
Principal investigator 1 Novo Nordisk AS $10,223.28 09/26/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 692458773
Principal investigator 1 Novo Nordisk AS $2,280.00 09/26/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 692458775
Principal investigator 1 Novo Nordisk AS $13.25 08/30/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692137
Principal investigator 1 Novo Nordisk AS $13.25 08/30/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692139
Principal investigator 1 Novo Nordisk AS $124.95 08/30/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692141
Principal investigator 1 Novo Nordisk AS $22.50 08/30/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692143
Principal investigator 1 Novo Nordisk AS $150.00 08/30/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692145
Principal investigator 1 Novo Nordisk AS $16.25 08/30/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692147
Principal investigator 1 Novo Nordisk AS $24.50 08/30/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692149
Principal investigator 1 Novo Nordisk AS $90.00 08/30/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692151
Principal investigator 1 Novo Nordisk AS $9.99 08/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692129
Principal investigator 1 Novo Nordisk AS $23.06 08/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692131
Principal investigator 1 Novo Nordisk AS $9.99 08/20/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692125
Principal investigator 1 Novo Nordisk AS $23.06 08/20/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692127
Principal investigator 1 Novo Nordisk AS $2.65 08/12/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692085
Principal investigator 1 Novo Nordisk AS $1.08 08/12/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692087
Principal investigator 1 Novo Nordisk AS $11.38 08/12/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692089
Principal investigator 1 Novo Nordisk AS $4.80 08/09/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692081
Principal investigator 1 Novo Nordisk AS $4.80 08/09/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692083
Principal investigator 1 SANOFI US SERVICES INC. $11,300.00 08/06/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691571806
Principal investigator 1 Novo Nordisk AS $3,000.00 07/31/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 692458769
Principal investigator 1 Novo Nordisk AS $1,000.00 07/31/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 692458771
Principal investigator 1 SANOFI US SERVICES INC. $3,636.00 07/30/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin as Monotherapy in Patients With Type 2 Diabetes Mellitus Who Have No dispute reported 06/30/2026 691571389
Principal investigator 1 Novo Nordisk AS $7.95 07/08/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692059
Principal investigator 1 Novo Nordisk AS $74.97 07/08/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692061
Principal investigator 1 Novo Nordisk AS $13.50 07/08/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692063
Principal investigator 1 Novo Nordisk AS $90.00 07/08/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692065
Principal investigator 1 Novo Nordisk AS $9.75 07/08/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692067
Principal investigator 1 Novo Nordisk AS $14.70 07/08/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692069
Principal investigator 1 Novo Nordisk AS $54.00 07/08/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706692071
Principal investigator 1 SANOFI US SERVICES INC. $9,184.00 06/25/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691556203
Principal investigator 1 SANOFI US SERVICES INC. $50.00 06/13/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691555819
Principal investigator 1 Novo Nordisk AS $1.14 06/12/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706691977
Principal investigator 1 Novo Nordisk AS $11.38 06/12/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706691979
Principal investigator 1 Novo Nordisk AS $9.98 06/12/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706691981
Principal investigator 1 Novo Nordisk AS $5.30 06/12/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706691983
Principal investigator 1 Novo Nordisk AS $49.98 06/12/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706691985
Principal investigator 1 Novo Nordisk AS $9.00 06/12/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706691987
Principal investigator 1 Novo Nordisk AS $60.00 06/12/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706691989
Principal investigator 1 Novo Nordisk AS $6.50 06/12/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706691991
Principal investigator 1 Novo Nordisk AS $9.80 06/12/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706691993
Principal investigator 1 Novo Nordisk AS $36.00 06/12/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706691995
Principal investigator 1 Novo Nordisk AS $63.52 06/10/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706691953
Principal investigator 1 SANOFI US SERVICES INC. $2,022.00 05/30/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin as Monotherapy in Patients With Type 2 Diabetes Mellitus Who Have No dispute reported 06/30/2026 691555631
Principal investigator 1 Novo Nordisk AS $117.78 05/15/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706691975
Principal investigator 1 SANOFI US SERVICES INC. $9,300.00 05/13/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691555079
Principal investigator 1 SANOFI US SERVICES INC. $3,000.00 05/09/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691554879
Principal investigator 1 Novo Nordisk AS $144.09 05/07/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706691973
Principal investigator 1 SANOFI US SERVICES INC. $108.00 05/06/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691554855
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 04/29/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691554661
Principal investigator 1 SANOFI US SERVICES INC. $3,336.00 04/25/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691554439
Principal investigator 1 SANOFI US SERVICES INC. $50.00 04/25/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691554443
Principal investigator 1 SANOFI US SERVICES INC. $5,322.00 04/25/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691554449
Principal investigator 1 SANOFI US SERVICES INC. $144.00 04/25/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691554463
Principal investigator 1 SANOFI US SERVICES INC. $9,675.00 04/22/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin as Monotherapy in Patients With Type 2 Diabetes Mellitus Who Have No dispute reported 06/30/2026 691556895
Principal investigator 1 Novo Nordisk AS $10,149.40 03/29/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9535-4270 No dispute reported 06/30/2026 692458763
Principal investigator 1 SANOFI US SERVICES INC. $14,782.00 03/21/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691549477
Principal investigator 1 Novo Nordisk AS $8,913.20 02/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9068-4228 No dispute reported 06/30/2026 692458765
Principal investigator 1 Novo Nordisk AS $1,000.00 02/21/2019 Non-covered Recipient Entity
JUNO RESEARCH
NN9924-4223 No dispute reported 06/30/2026 692458781
Principal investigator 1 SANOFI US SERVICES INC. $28,422.00 02/07/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691547123
Principal investigator 1 SANOFI US SERVICES INC. $34,300.00 01/22/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin as Monotherapy in Patients With Type 2 Diabetes Mellitus Who Have No dispute reported 06/30/2026 691547897
Principal investigator 1 SANOFI US SERVICES INC. $1,348.00 01/10/2019 Non-covered Recipient Entity
Veterinary Pharmacies
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin as Monotherapy in Patients With Type 2 Diabetes Mellitus Who Have No dispute reported 06/30/2026 691545673